CORRECTING and REPLACING Aegis Sciences Corporation Announces Expanded Testing for Marijuana
tennsun.com/10777845

Trending...
NASHVILLE, Tenn. ~ Aegis Sciences Corporation, a health care testing lab based in Nashville, Tenn., has announced an expansion of their urine testing for marijuana and other cannabinoids. The updated test will now include Delta‐8 Carboxy‐THC and Cannabidiol, in addition to Delta‐9 Carboxy‐THC.

Delta‐8 and delta‐9 THC are psychoactive cannabinoids that are subject to variable state and federal regulations. Cannabidiol is also a cannabinoid that is not known to be psychoactive. These cannabinoids can be found in many different products including, but not limited to, liquids used for electronic cigarettes (i.e., vapes) edibles, and drinks.

Dr. Josh Schrecker, Sr. Dir. Of Clinical Affairs at Aegis Sciences Corporation said the goal of expanding the definitive cannabinoid testing is "to provide additional detail and insight for providers when these substances are detected" as alternative cannabinoids have become more widely available. He added that although urinary concentrations of these markers do not provide absolute identification of the product used or its consistency, it will assist providers in identifying recent use of alternative cannabinoids to drive more informed assessment and discussion with those they treat.

More on tennsun.com
Dr. Rebecca Heltsley, Senior Vice President, Research and Development at Aegis Sciences Corporation said the expansion of their marijuana assay "demonstrates our commitment to providing the most relevant testing available to healthcare providers". Health care practitioners can learn more about the updated test offering through the Aegis website: https://www.aegislabs.com

Aegis Sciences Corporation has taken a step forward in providing healthcare practitioners with more detailed information on marijuana use by expanding their urine testing for marijuana and other cannabinoids to include Delta‐8 Carboxy‐THC and Cannabidiol, in addition to Delta‐9 Carboxy‐THC. This will allow providers to identify recent use of alternative cannabinoids which will help them make more informed assessments when treating patients who have used such substances.
Filed Under: Business

Show All News | Report Violation

0 Comments

Latest on tennsun.com